The company realized sales of $0.3M in the BayMedica segment for the for the three months ended September 30, 2022, the result of the manufacturing and sale of bulk rare cannabinoid products following the acquisition of BayMedica in October 2021. As the period ended September 30, 2021 predated the acquisition of BayMedica, there are no comparable revenues in 2021.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on INM:
- InMed Pharmaceuticals Supports Epidermolysis Bullosa Awareness Week
- What You Missed On Wall Street On Monday
- What You Missed On Wall Street This Morning
- InMed Pharmaceuticals reports FY22 EPS ($33.17) vs. ($37.96) last year
- InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update